Abstract.
The 28th Joint Conference of the Parasitic Diseases Panels of the U.S.-Japan Cooperative Medical Sciences Program held in Baltimore, Maryland focused on current research within both countries on antiparasitic chemotherapy.
This meeting report sum marizes presentations of work in progress on antiparasitic drugs currently in use and drugs under development or in clinical trials, as well as reports on potentially unique parasite characteristics that may provide targets for development of future therapeutics.
as well as other members of the research com munity within the U.S., Japan, and other South east Asian countries. These meetings are open to the public. The 28th Joint Conference of the Parasitic Diseases Panels of the U.S.-Japan Cooperative Medical Science Program was held in Baltimore, Maryland July on 19â€"22, 1993 . It covered as pects of the immunology, cell biology, epide miology, and vector biology of malaria, schis tosomiasis, filanasis and trypanosomes. This report summarizes the discussions from a mini symposium on antiparasitic chemotherapy, which was a major focus of the conference.
DRUGS IN CURRENT USE

Artemisinin.
Derivatives of artemisinin are used widely because they are one of the few effective treatments for multi-drug resistant Plasmodium falciparum malaria. Understanding the mechanism of artemisinin action may aid in the development of better second generation drugs. Data presented by Steve Meshnick from the University of Michigan (Figure 1) suggest that artemisinin has a two step mechanism of action.'-3 First, the drug interacts with intrapar asitic heme that catalyzes its conversion into a free radical. Second, the free radical form of the drug alkylates critical malarial proteins. Evi dence for the first step is based on electron spin resonance spectroscopy and cyclic voltammetry studies that demonstrate that heme can catalyze The U.S.-Japan Cooperative Medical Sciences Program was established in 1965 by joint agree ment of the President of the United States and the Prime Minister of Japan. The bilateral pro gram was organized to promote cooperative re search on health problems of recognized impor tance in Southeast Asia. Parasitic disease was one of the five original areas selected for collab orative research at that time. Currently, other Panels affiliated with the Program include chol era, leprosy, tuberculosis, viral diseases, hepati tis, malnutrition, environmental mutagenesis and carcinogenesis, and the acquired immunodefi ciency syndrome (AIDS). There is also an im munology board intended to provide expertise in this fundamental area of research. The first char ter of scientific guidelines to the Parasitic Dis eases Panel specified that the research concerns be confined to schistosomiasis and filariasis, mainly due to their important impact on world health and economic development. In 1985, however, the guidelines were expanded and re search on malaria and other vector-borne para sitic diseases was incorporated into the program. Annual conferences are held alternatively in the U.S. and Japan. Participants include members of the U.S. and Japanese Parasitic Diseases Panels heme that catalyzes its conversion into a free radical. Second, the free radical form of the drug alkylates critical malarial proteins.
the opening of the drug's endoperoxide bridge. The fact that iron chelators and free radical scav engers antagonize the antiplasmodial activity of artemisinin in vitro suggests that heme-induced degradation of the endoperoxide bridge may be important in vivo. Evidence for the second al kylation step is based on two observations: 1) alkylation of human serum albumin by artemi 5mmin vitro,and 2) sodiumdodecylsulfategel autoradiograms that demonstrate the alkylation of parasite proteins by radiolabeled drug.
Studies presented by Mamoru Suzuki from Gunma University suggest that artemether has a rapid onset of action in vivo in P. falciparum infected Aotus monkeys.4 Distinct morphologic changes were seen within 2 hr and viable para sites disappeared within 66 hr, although dead in traerythrocytic parasites persisted in the circu lation for up to 10 days. Ultrastructural studies showed marked swelling and disruption of the inner membrane of parasite mitochondria within 2 hr. Late changes included clumping of ribo somes and the appearance of electron dense ma terial in the nucleus. Together these observations suggest that mitochondria, which contain many hemoproteins, may be an important target for artemisinin. If this hypothesis is correct, addi tional information will be required to explain the specificity of artemisinin, i.e., why are the ar temisinin concentrations that inhibit parasite growth by damaging their mitochondria not tox ic also for mammalian cells at those concentra tions? Dihydrofolate reductase (DHFR) inhibi tors. Toshihiro Hon from Osaka University has used a novel approach to study the action of DHFR inhibitors against the P. falciparum DHFR in vitro. To circumvent problems asso ciated with the expression of AT-rich parasite DNA in Escherichia coli, he synthesized an ar tificial P. falciparum DHFR gene in vitro using characteristic E. coli codons to produce the de sired amino acid sequence of the parasite DHFR.5 Expression of this construct in E. coli yielded -â€˜-30%of cell protein as the parasite DHFR. Because most of the parasite DHFR was in aggregates, it did not demonstrate enzymatic activity. However, after solubilization and ren aturation, the enzymatic activity, K11,,and V,,,,, of the parasite DHFR were similar to those of the purified bifunctional P. falciparum DHFR thymidylate synthase complex,6 and K@svalues were similar to those obtained previously with known inhibitors. This recombinant parasite en zyme is now being used to test candidate DHFR inhibitors in vitro.
Single-dose diethylcarbamazine (DEC) ver sus ivermectin.
In previous studies, DEC has been given in doses of 50â€"100 mg three times a day for up to 21 days, and has frequently pro duced severe limiting side effects. In contrast, ivermectin has been given as a single dose every 6â€"12 months and has had a much lower inci dence of side effects. James Kazura from Case Western Reserve University reported a study from Papua New Guinea in which single doses of DEC and ivermectin were compared in per sons with bancroftian filariasis. Although the ini tial decrease in microfilaremia was greater in the ivermectin group, the results with DEC and iver mectin were similar at 90 and 180 days. (Fig  ure 2) indicate that the critical first step in hemoglobin degradation is cleavage of the a chain by an aspartic protease between residues 33 (Phe) and 34 (Leu).'3 Examination of multi ple hemoglobin sequences has shown that this cleavage site is retained in all known human he moglobins. The gene for this enzyme has now been cloned and found to be homologous to hu man renin and cathepsin D, although it has an unusually long propiece with a hydrophobic re gion consistent with a membrane spanning do main. The second enzyme involved in the pro teolysis of hemoglobin is an unusual cysteine protease that appears to function only after the initial aspartic protease cleavage. These results suggest that the proteolysis of hemoglobin by plasmodia is a highly ordered process,'4 and that it may be possible to design specific inhibitors Ivermectin markedly reduces the number of microfilariae in the skin of per sons with onchocerciasis.
In a prospective study carried out in Guatemala, Edward Cupp from the University of Arizona reported that ivermectin also reduced the transmission of onchocerciasis. In a three-year study, four six-monthly treat ments with ivermectin reduced both the preva lence and intensity of microfilarial infection in the black fly vector.9 This change was associated with an 80â€"100% reduction in transmission as measured by a decrease in the numbers of in fective stage larvae in the Simulium ochraceum.
Repetitive treatment cycles also affected adult worms, increasing the proportions of uninsemi nated, damaged, and dead female worms in sub cutaneous nodules.'Â°These results are consistent with a direct drug effect on adult male and fe male worms in vivo.
of this process that have antiplasmodial activity both in vitro and in vivo.
Topoisomerase II in trypanosomes The mi tochondrial (kinetoplastid or k) DNA of the try pansosomes that cause African sleeping sickness contains thousands of interlocked maxi-(--'-20 kb) and mini-(---1 kb) circles that must undergo many changes during replication and transcrip tion. These reactions are catalyzed by topoiso merases, which are inhibited by a number of drugs in current use as antitumor or antibacterial agents: etoposide, adriamycin, amsacrine, nali dixic acid, and the fluoroquinolones. P. falciparum in vitro'7 and P. yoelii in vivo (unpublished data) . More recent studies indicate that the concentrations of 5-fluoroorotic acid necessary to inhibit clonal viability of par asites correlate well with those that inhibit thym idylate synthase activity, and thus suggest that the mechanism responsible for this effect is in hibition of the parasite thymidylate synthase@ Ion channels in Plasmodia. Patch clamping, which has generally been used with much larger cells such as squid axons, has not been techni cally feasible previously for either the parasite or its host red blood cell (RBC). After removing the intervening RBC membrane and forming gi gaohm seals on the small (3â€"5p.m) parasite, Dc sai and his colleagues were able to study trans port across the parasitophorous vacuole membrane (PVM), the outer of the two parasite membranes. This approach identified a 140 pS channel on the PVM, which is permeable to both cations and anions, such as lysine@, Tris@, @ Mg@, and glucuronate.'9 This channel is pres ent at high density and is open more than 98% of the time at the resting potential of the PVM. Together with a new Ca@+ pathway in the mem brane of the RBC,2Â°these studies provide evi dence for parasite-induced channels that are po tentially unique chemotherapeutic targets. Neither channel is affected by chloroquine, and both are similar in chioroquine-susceptible and -resistant parasites.
Proteases in schistosomes. James McKerrow and his colleagues at the University of California in San Francisco have performed a series of studies on rationale drug design using computer modeling of the schistosomal serine protease that cercariae use to cross the skin and infect humans.2' Based on x-ray diffraction data for similar proteases that have been crystallized, computer modeling was used to create a model of the cercarial serine protease and to examine the interaction with inhibitors using computer graphics. Using this strategy, four of the 40 pu tative inhibitors identified by computer modeling were found to have K1s values < 100 pM and are therefore being subjected to further study.22 These studies support the idea that specific in hibitors of parasite enzymes that are effective in vitro and in vivo can be developed with the as sistance of computer modeling. Additional stud ies with peptidomimetic inhibitors have con firmed that cysteine proteases of Schistosoma mansoni and Trypanosoma cruzi can be selec tively inhibited in vitro and in vivo without tox icity at concentrations that interrupt the parasite life cycle. 
